Medtronic Showcases Aortic Leadership in Innovation with Clinical Release and Pipeline at VEITH 2015
November 16 2015 - 9:00AM
New Aortic Data
Demonstrates Medtronic's Commitment to Innovation
DUBLIN - November 16, 2015 -
Medtronic plc (NYSE: MDT) today announced notable clinical studies
and innovative technologies that will be presented at the annual
VEITHsymposium, the world's premier conference for vascular
surgeons specializing in the most current information and new
developments in clinical practice and research. The conference is
taking place in New York City from November 17-21, 2015.
"Leveraging decades of clinical experiences and
data, our core technologies for treating abdominal aortic aneurysm
(AAA) and descending thoracic disease, Endurant® and Valiant® product lines, have been proven in more
than 280,000 patients globally," said Daveen Chopra, vice president
and general manager of the Aortic business, which is part of the
Aortic & Peripheral Vascular division at Medtronic. "Our
mission to improve patient outcomes drives our commitment to build
on our success and invest in complementary innovative technology
that will allow physicians to treat more complex aortic
disease."
The VEITHsymposium will begin with a special
session focusing on new developments in AAA and endovascular
aneurysm repair (EVAR). This session will feature the highly
anticipated four-year subset results on hostile neck anatomies from
the ENGAGE Global Registry for Medtronic's Endurant AAA stent graft
system. Hence J.M. Verhagen, M.D., Ph.D., Professor and Chief of
Vascular Surgery, Erasmus University Medical Center in Rotterdam,
the Netherlands, will present this real-world data on the opening
day of VEITH. Additionally, four-year results from the full ENGAGE
registry cohort will be presented on Saturday, November 21, 2015,
by Marc R.H.M van Sambeek, M.D., Ph.D, Department of Vascular
Surgery, Catharina Hospital, Eindhoven, the Netherlands.
Medtronic's recently acquired EndoAnchor system
will also be highlighted in nine presentations examining clinical
applicability. The Heli-FX® EndoAnchor® system is an endovascular
deployed anchor designed to attach a variety of aortic endografts
to the native vessel wall.
Finally, several Medtronic products in clinical
trials will be highlighted, such as the Endurant® Evo AAA stent
graft system, as well as products for complex aortic disease,
including:
-
Modified Valiant devices used in the treatment
of ascending arch disease.
-
One-year results from the early feasibility of
the Valiant "Mona LSA®" branch thoracic stent graft system.
-
The initial experience in the treatment of
thoracoabdominal with modified Medtronic stent grafts.
Key Events:
Tuesday, November 17
- 6:51 am - 6:56 am
Redefining Adverse Neck Morphology With Newer EVAR
Devices Which Perform Better In Short, Angulated, and Large
Diameter Necks And Those With A Thrombus Burden: What Are the
Limits?, from the ENGAGE Registry
- 7:20 am - 7:25 am Endograft
Repair Of Ascending Aortic Lesions And Type A Dissections With A
Physician Sponsored IDE (PSIDE) For A Modified Valiant Device:
Lessons Learned And What Are The Prospects For An Endograft-Valve
Combined Device?
- Noon - 1 pm Treating
Challenging Anatomies in TEVAR and EVAR. New York Hilton Midtown,
Gramercy West 2nd Floor, a
Medtronic sponsored event
Wednesday, November 18
- 9:05am - 9:09 am DEBATE:
EVAR With Short Necks Are Best Treated With Standard EVAR Using
Newer Endograft Devices
Thursday, November 19
- 7:46am - 7:51am Newly
Modified Medtronic Endurant (Evo) Endograft (investigational
device): Initial Clinical Experience And Advantages
- 10:17am - 10:22am A New
Manifold Branched Endograft Device (investigational device) For
Treating TAAAs And Other Complex Aortic Lesions: Concept,
Advantages, Initial Clinical Experience
- 11:26am - 11:31am The
Medtronic Branched TEVAR Endograft, The Valiant Mona LSA System
(investigational device): Technique, Advantages and Results
- 3:40pm - 4:47pm Session 61:
Preventing And Treating Migration and Endoleaks: Update on Heli-Fx
EndoAnchors
Details such as times, titles and
locations are subject to change.
In collaboration with leading clinicians,
researchers and scientists worldwide, Medtronic offers the broadest
range of innovative medical technology for the interventional and
surgical treatment of cardiovascular disease and cardiac
arrhythmias. The company strives to offer products and services
that deliver clinical and economic value to healthcare consumers
and providers around the world.
About VEITH
symposium
Now in its 42nd year,
VEITHsymposium provides vascular surgeons, interventional
radiologists, interventional cardiologists and other vascular
specialists with a unique and exciting format to learn the most
current information about what is new and important in the
treatment of vascular disease. The 5-day event features rapid-fire
presentations from world renowned vascular specialists with
emphasis on the latest advances, changing concepts in diagnosis and
management, pressing controversies and new techniques. For more
information, please visit www.VEITHpress.org or contact Pauline T.
Mayer at 631.979.3780.
About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin,
Ireland, is among the world's largest medical technology, services
and solutions companies - alleviating pain, restoring health and
extending life for millions of people around the world. Medtronic
employs more than 85,000 people worldwide, serving physicians,
hospitals and patients in approximately 160 countries. The company
is focused on collaborating with stakeholders around the world to
take healthcare Further, Together.
Any forward-looking statements
are subject to risks and uncertainties such as those described in
Medtronic's periodic reports on file with the Securities and
Exchange Commission. Actual results may differ materially from
anticipated results.
-end-
Contacts:
Krystin Hayward
Public Relations
+1-508-261-6512
Ryan Weispfenning
Investor Relations
+1-763-505-4626
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Medtronic plc via Globenewswire
HUG#1966922
Medtronic (NYSE:MDT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medtronic (NYSE:MDT)
Historical Stock Chart
From Apr 2023 to Apr 2024